DOCSLIB.ORG

Leading from Our Strengths

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leading from Our Strengths 1999 ANNUAL REPORT Leading from Our Strengths Credo Values Decentralized Management Multiple Growth Platforms Global Reach Research & Development Partnering with Others Innovation Focus on the Long Term Leadership Brands Three Years in Brief–Worldwide % Change (Dollars in Millions Except Per Share Figures) 1999 1998 1997 1999 1998 Sales to customers $27,471 23,995 22,830 14.5 5.1 Net earnings* 4,167 3,003 3,311 38.8 (9.3) Cash dividends paid 1,479 1,305 1,137 13.3 14.8 Shareowners’ equity 16,213 14,077 12,866 15.2 9.4 Percent return on average shareowners’ equity* 27.5 22.3 27.4 – – Per share Net earnings – basic* $ 3.00 2.16 2.40 38.9 (10.0) – diluted* 2.94 2.12 2.34 38.7 (9.4) Cash dividends paid 1.09 0.97 0.85 12.4 14.1 Shareowners’ equity 11.67 10.13 9.26 15.1 9.5 1 7 7 Market price (year-end close) 93 /4 83 /8 64 /8 11.2 29.3 Average shares outstanding (millions) – basic 1,390.1 1,389.8 1,380.6 0.0 0.7 – diluted 1,418.2 1,417.2 1,415.4 0.1 0.1 Shareowners of record (thousands) 169.4 168.9 160.0 0.3 5.6 Number of employees (thousands) 97.8 94.3 91.1 3.7 3.5 * Net earnings and earnings per share for 1999 and 1998 include special charges of $42 million or $.03 diluted earnings per share for 1999 and $697 million or $.49 diluted earnings per share in 1998. These special charges include costs associated with the Centocor merger in 1999 and Restructuring and In-Process Research and Development charges in 1998. Excluding the impact of these charges, 1999 net earnings increased 13.8% over 1998. The percent return on average shareowners' equity in 1999 before these charges is 27.8%. For detailed discussion of these charges, refer to Note 14 and Note 17 of the Notes to Consolidated Financial Statements. Description of the Company Johnson & Johnson has $27.5 billion in sales and is the world’s most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical and professional markets. Johnson & Johnson has 97,800 employees and 190 operating companies in 51 countries around the world, selling products in more than 175 countries. Letter to Shareowners e are pleased to report that 1999 was a very good year for Johnson & Johnson as we continued to deliver strong double-digit growth in both sales and earnings. Our invest- mentsW in a broad range of opportunities, both internally and outside the Company, have allowed us to grow at an accelerated rate and provide a strong platform for future growth. Our sales and earnings ended the year in record-break- ing territory. With revenue of $27.5 billion, an increase of 14.5% over 1998, the Company has achieved 67 consecu- tive years of sales increases. Net earnings for the year crossed the $4 billion level for the first time to $4.2 billion, an increase of 13.8% over the $3.7 billion achieved in 1998 — excluding special merger charges in 1999 and the 1998 reconfiguration of our worldwide manufacturing network and in-process research & development charges. Earnings per share rose to $2.97 for the year, an increase of 13.8%, compared with $2.61 per share in 1998, exclud- ing the special charges. Enabled by our strong cash flow, we increased our divi- dend to shareowners by 12% — our 37th consecutive year of dividend increases. Our total return to shareown- ers, including reinvestment of dividends, has grown at a compounded annual rate of 22.1% over the past 10 years, and 29.6% over the past five years. Ralph S. Larsen, Chairman and Chief Executive Officer The biggest news in 1999 was our largest merger ever, the $4.9 billion stock-for-stock transaction with Centocor, Inc. Centocor, a leader in monoclonal antibody technology and immunology and acute vascular care products, business through internal development combined with strengthens several of our existing growth platforms, includ- selective acquisitions that strengthen our market or tech- ing biotechnology. With Centocor and our Ortho Biotech nological position. affiliate, Johnson & Johnson has now become a world leader Our track record over the years flows directly from a in biotechnology. unique combination of underlying strengths that have Our financial position remains strong and we continue allowed us to sustain impressive growth and create endur- to be one of only six U.S. industrial corporations to maintain ing value over many years. To provide greater insight a Triple A credit rating. Our strong cash flow, combined into these key drivers of our success, the theme of this year’s with our Triple A status, has enhanced our ability to con- Annual Report is “Leading from Our Strengths.” summate more than $9 billion in mergers, acquisitions, While we have a well-earned reputation for marketing and various other third party partnerships over the past consumer and health care products, at its very core Johnson two years. & Johnson is a science-based corporation. In recent months we have seen some large mergers in Last year we committed $2.6 billion to research & develop- the pharmaceutical industry. We expect there will be ment and anticipate an investment of close to $3 billion in others. Fortunately, with total revenues approaching the 2000. We continue to set our sights ever higher, as medical $30 billion mark, Johnson & Johnson has the size and science evolves at an extraordinary rate, opening whole scale to compete aggressively in this changing landscape. new horizons for discovery research, product development We will continue to focus our energies on building our and innovation in all manner of treatments and therapies. 1 comes data that support the efficacy of our products and expansion of direct-to-consumer advertising through which we make consumers more knowledgeable about the bene- fits of our prescription medicines. We now market more than 100 prescription medicines in 150 countries. Of these, 33 products had 1999 sales in excess of $50 million, with 20 of them in excess of $100 million. In the Professional segment, which introduced numer- ous new products, worldwide sales increased 15.7% over 1998, with the addition of DePuy’s orthopaedic products; strong growth from Ethicon Endo-Surgery’s laparoscopy and mechanical wound closure products; solid contribu- tions from Ethicon, Inc. through its Mitek suture anchors and Gynecare’s women’s health products; continued growth in disposable contact lenses from Vistakon, and steady progress from Cordis. A number of new stents were introduced by Cordis and its most recent was the BX VELOCITY coronary stent — launched in Europe, where it has been well received by the medical community. Worldwide Consumer segment sales for 1999 were par- ticularly hard hit by negative currency adjustments of 3.5% reflecting primarily the strength of the U.S. dollar against the Euro and several Latin American currencies. Despite this currency impact, our consumer sales increased by 5.2% over the prior year. Solid growth was led by positive consumer acceptance of a newly introduced line of cosmet- Robert N. Wilson, Vice Chairman of the Board ics from Neutrogena, as well as continued strength in Neu- trogena’s base business. Also in the skin care franchise, we experienced good performances by the RoC, AVEENO, Our Pharmaceutical segment had a worldwide sales CLEAN & CLEAR and JOHNSON’S pH5.5 product lines. increase last year of more than 20% over 1998. Pharma- The adult and children’s TYLENOL and MOTRIN lines of ceutical growth reflected the strong performance of analgesic products rounded out the continued growth of PROCRIT, for the treatment of anemia; RISPERDAL, an our Consumer segment. antipsychotic medication; DURAGESIC, a transdermal Our entry into the nutraceuticals business with the patch for chronic pain; LEVAQUIN, an anti-infective, BENECOL line of cholesterol-lowering products is off to a and the oral contraceptive line of products. In the latter slower start than we had hoped initially. part of the year we received marketing approval from the We are focusing our attention on increased levels of FDA for ORTHO-PREFEST, for hormone replacement professional education which will help establish BENECOL therapy, and an additional indication for REMICADE for products as an important part of the health-conscious the treatment of rheumatoid arthritis. On the negative side, consumer’s cholesterol-lowering regimen. BENECOL is doing PROPULSID, a gastrointestinal motility medicine, experi- quite well in the United Kingdom, where we are gaining enced a sales decline as Janssen, in cooperation with the important marketing insights. FDA, implemented stronger label directions cautioning Among the challenges facing our industry is the ongoing against its use by certain patients and in conjunction with debate about changes to the health care system in the United certain other medications. States. Our view is that the public and private sectors need The growth of our pharmaceutical business has been to work together to develop sensible ways of providing health driven by a number of factors including good clinical out- insurance coverage for people who either cannot afford, 2 cannot obtain or simply decide to take their chances and person per day on alcohol … $.92 on electricity and $1.05 not purchase health insurance. per day getting our cars repaired. (Source: U.S. Depart- In addition, while about two thirds of the nation’s senior ment of Commerce, Bureau of Economic Analysis, 1998) citizens have some form of insurance coverage for pre- scription medicines, one third do not.
Load more

Recommended publications
  • Gelatina Di K-Y Da Wikipedia, L'enciclopedia Libera Salto A: Navigazione, Ricerca
    Gelatina di K-Y Da Wikipedia, l'enciclopedia libera Salto a: navigazione, ricerca /wiki/Image:K-Y.jpg/wiki/Image:K-Y.jpg /wiki/Image:K-Y.jpgUn tubo della gelatina di K-Y La gelatina di K-Y, anche conosciuta come la gelatina di Panitsa, è un lubrificante personale a base d'acqua e solubile in acqua prodotto da Johnson & Johnson. Le iniziali “K-Y„ non sono conosciute per rappresentare alcune parole - sono state descritte dal loro creatore come “lettere arbitrarie„ - ma sono mantenute per la loro marca- identità. È stato introdotto nel gennaio 1904 dal creatore Van Horn & Sawtell del suturare e farmaceutico di New York City, [1] e più successivamente acquistato da Johnson & Johnson, scopo dichiarato originale della gelatina di K-Y come lubrificante chirurgico ed è stato scelto spesso dai medici a causa della relativa base vegetale. Il prodotto ora è più ampiamente usato come lubrificante sessuale. Non reagisce con i condoms del lattice o il silicone gomma-ha basato i giocattoli del sesso. Mentre non suggerito per ingestione, ha un gusto dello sweetish, in modo da non interferire con il sesso orale. Ha una consistenza spessa e una tendenza asciugarsi durante l'uso, ma può “essere riattivato„ tramite l'aggiunta della saliva o di più acqua. La gelatina di K-Y non contiene uno spermicide. Una formulazione con nonoxynol-9 era disponibile, ma Johnson & Johnson lo ha tirato dal mercato dopo l'individuazione che potrebbe aiutare il HIV a spargersi. [2] Il prodotto può anche essere usato per gli scopi di lubrificazione quando prende la temperatura corporea dal retto.
    [Show full text]
  • Amity University
    AMITY UNIVERSITY We nurture talent --------------------UTTAR PRADESH-------------------- (Established by Ritnand Balved Education Foundation) THIS IS TO CERTIFY THAT PROJECT REPORT ENTITLED “PROBLEM IDENTIFICATION AND RECTIFICATION IN CLAIM SETTLEMENT”, IN JOHNSON & JOHNSON, NEW DELHI IS PREPARED BY DEEPAK BEHAL OF MBA (GENERAL) 3rd SEMESTER, AMITY UNIVERSITY, LUCKNOW CAMPUS, UNDER MY SUPERVISION. PLACE: LUCKNOW FACULTY GUIDE: DATE: (DR. NIMISH GUPTA) STUDENT’S CERTIFICATE Certified that this report is prepared based on the summer internship project undertaken by me in Johnson & Johnson from 4th June 2007 to 16th July 2007, under the able guidance of Mr. Ajay Rangaraj, Regional Manager, sales (north) in partial fulfilment of the requirement for award of degree of Master in Business Administration From Amity University Uttar Pradesh. Date: _____________ Signature: __________ Signature: __________ Signature: __________ Name: _____________ Name: _____________ Name: _____________ Student Faculty Guide Director ABS ACKNOWLEDGEMENT The satisfaction and Euphoria that accompany the successful completion any task would be without the mention of people who make it possible and whose constant guidance and encouragement leads all effects with success. I would like to express my sincere and profound gratitude to my project guide Dr. Nimish gupta who has been a constant source of inspiration throughout my project. I thank him for the guidance given by him to complete my project. I would also like to thank my Industry guide Mr. Ajay Rangaraj who has been of great help to me and helping me whenever I needed help. Last but not the least I would like to thank Mr. Sabharwal (ABI), Mr Harish rathuri(ABI), Mr Kashif Husain(ABI), Mr Ramesh Jaswani(ABI), Mr Suresh Nandwani(FLM), and all the staff of Johnson & Johnson who helped me in successful completion of the project without them it would have been very difficult for me to complete the project successfully.
    [Show full text]
  • Johnson & Johnson
    9/9/13 Johnson & Johnson - Wikipedia, the free encyclopedia Johnson & Johnson Coordinates: 40°29′55″N 74°26′37″W From Wikipedia, the free encyclopedia Johnson & Johnson is a U.S multinational Johnson & Johnson medical devices, pharmaceutical and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Type Public Average and the company is listed among the Fortune 500. Traded as NYSE: JNJ (http://www.nyse.com/about/listed/lcddata.html? Johnson & Johnson ranked at the top of ticker=jnj) Harris Interactive's National Corporate Dow Jones Industrial Average Component Reputation Survey for seven consecutive S&P 500 Component years up to 2005,[2] was ranked as the world's most respected company by Industry Medical equipment Barron's Magazine in 2008,[3] and was the Pharmaceutical first corporation awarded the Benjamin Founded 1886 Franklin Award for Public Diplomacy by Founder(s) Robert Wood Johnson I, the U.S. State Department in 2005 for its James Wood Johnson, funding of international education programs. Edward Mead Johnson However, in recent years the company's reputation has been adversely affected by Headquarters New Brunswick, New Jersey, United States product recalls, fines for pharmaceutical Area served Worldwide marketing practices, litigation with a group of shareholders, and other legal issues. Key people William Weldon (Chairman of the Board) Johnson & Johnson is headquartered in Alex Gorsky New Brunswick, New Jersey with the (Chief Executive Officer) consumer division being located in Products See list of Johnson & Johnson products Skillman, New Jersey. The corporation includes some 250 subsidiary companies Revenue US$ 65.030 billion (2012)[1] with operations in over 57 countries and Operating US$ 12.361 billion (2012)[1] products sold in over 175 countries.
    [Show full text]
  • Title of Each Class Name of Each Exchange on Which Registered
    1 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JANUARY 3, 1999 COMMISSION FILE NUMBER 1-3215 JOHNSON & JOHNSON (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) NEW JERSEY 22-1024240 (State of (I.R.S. Employer Incorporation) Identification No.) ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NEW JERSEY 08933 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED ------------------- ----------------------------------------- Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [ ] The aggregate market value of the voting stock held by non-affiliates of the registrant on February 23, 1999 was approximately $117.2 billion.
    [Show full text]
  • Sustainable Organization of a Lean Six Sigma Program: a Competing Values Perspective
    Georgia State University ScholarWorks @ Georgia State University Business Administration Dissertations Programs in Business Administration 8-1-2020 Sustainable Organization of a Lean Six Sigma Program: A Competing Values Perspective Marilyn J. Tom Follow this and additional works at: https://scholarworks.gsu.edu/bus_admin_diss Recommended Citation Tom, Marilyn J., "Sustainable Organization of a Lean Six Sigma Program: A Competing Values Perspective." Dissertation, Georgia State University, 2020. https://scholarworks.gsu.edu/bus_admin_diss/138 This Dissertation is brought to you for free and open access by the Programs in Business Administration at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Business Administration Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. PERMISSION TO BORROW In presenting this dissertation as a partial fulfillment of the requirements for an advanced degree from Georgia State University, I agree that the Library of the University shall make it available for inspection and circulation in accordance with its regulations governing materials of this type. I agree that permission to quote from, to copy from, or publish this dissertation may be granted by the author or, in his/her absence, the professor under whose direction it was written or, in his/her absence, by the Dean of the Robinson College of Business. Such quoting, copying, or publishing must be solely for scholarly purposes and does not involve potential financial gain. It is understood that any copying from or publication of this dissertation which involves potential gain will not be allowed without written permission of the author. Marilyn Jane Tom NOTICE TO BORROWERS All dissertations deposited in the Georgia State University Library must be used only in accordance with the stipulations prescribed by the author in the preceding statement.
    [Show full text]
  • 2002 Annual Report Three Years in Brief–Worldwide
    2002 Annual Report Three Years in Brief–Worldwide % Change (Dollars in Millions Except Per Share Figures) 2002 2001 2000 2002 2001 Sales to customers $36,298 $ 32,317 29,172 12.3 10.8 Net earnings* 6,597 5,668 4,953 16.4 14.4 Cash dividends paid 2,381 2,047 1,724 16.3 18.7 Shareholders’ equity 22,697 24,233 20,395 (6.3) 18.8 Percent return on average shareholders’ equity 28.1 25.4 26.5 – – Per Share Net earnings - basic 2.20 1.87 1.65 17.6 13.3 - diluted 2.16 1.84 1.61 17.4 14.3 Cash dividends paid 0.795 0.70 0.62 13.6 12.9 Shareholders’ equity 7.65 7.95 6.77 (3.8) 17.4 Market price (year-end close) 53.11 59.86 52.53 (11.3) 14.0 Average shares outstanding (millions) - basic 2,998.3 3,033.8 2,993.5 (1.2) 1.3 - diluted 3,054.1 3,099.3 3,099.2 (1.5) 0.0 Number of employees (thousands) 108.3 101.8 100.9 6.4 0.9 * Net earnings and earnings per share for 2002 include In-process research and development (IPR&D) charges of $189 million or .07 diluted earnings per share related to the acquisitions of Tibotec-Virco N.V. and Obtech Medical AG. Excluding the impact of these charges, 2002 net earnings increased 16.8% over 2001. Net earnings and earnings per share in 2001 and 2000 include $231 million or .07 diluted earnings per share and $45 million or .02 diluted earnings per share, respectively, related to IPR&D and ALZA merger costs in 2001 and IPR&D net of restructuring gains in 2000.
    [Show full text]
  • Neutrogena® Glow Boost Neu Ab März 2021
    Good to Glow: Neutrogena® Glow Boost Neu ab März 2021 Neuss, 1. März 2021. Der Spagat zwischen Familie, Karriere, Freunden und der nötigen Me-Time kann stressig sein, keine Frage. Das hält Frauen aber nicht davon ab, sich selbstbewusst den täglichen Herausforderungen zu stellen. Stress kann ihnen nichts anhaben – ihrer Haut allerdings schon. Sie verliert an natürlicher Strahlkraft und wirkt oft müde und fahl. Für strahlende Haut und gegen erste Zeichen der Hautalterung1 gehört Neutrogena® Glow Boost ab sofort in die Pflegeroutine jeder Powerfrau. Das Älterwerden jagt Frauen schon lange keine Angst mehr ein. Aber Hautalterung? Dafür ist es definitiv noch zu früh. Neutrogena Glow Boost ist die erste revitalisierende Gesichtspflege von Neutrogena, die die Haut strahlen lässt und gleichzeitig hilft, der Hautalterung vorzubeugen. Die Serie besteht aus Peeling, Serum, Tagespflege und LSF 30 Fluid und bildet eine abgestimmte Pflegeroutine mit wissenschaftlich bestätigten Formeln, die effektive Inhaltsstoffe enthalten. Wissenschaftliche Studien bestätigen die Effektivität der Produkte aus der Glow Boost Serie. Bis zu 96 % der Testerinnen bestätigen, dass ihre Haut nach der Verwendung gesünder aussieht und strahlender wirkt.2 Neutrogena Glow Boost - eine vollständige Pflegeroutine in nur drei Schritten für eine strahlende Haut: Das Revitalisierende Peeling mit Mandelsäure und natürlichen Peelingpartikeln reinigt und entfernt abgestorbene Hautzellen. Das Serum mit hochkonzentriertem Neoglucosamine® aktiviert den natürlichen Hauterneuerungsprozess und hilft, der Hautalterung vorzubeugen. Die Revitalisierende Tagespflege sorgt zudem für einen Extra-Frischekick. Für Schutz vor äußeren Umwelteinflüssen hilft alternativ das LSF 30 Fluid mit Vitamin C&E und UV-Schutz. Die leichte Textur und milde Formulierung der Produkte beschwert nicht und ist für alle Hauttypen geeignet – für eine geschmeidige, strahlende und gesund aussehende Haut.
    [Show full text]
  • Johnson & Johnson
    21 January 2013 GLOBAL IDEAS www.anchorcapital.co.za www.investorcampus.com Johnson & Johnson — just the right medicine Business Overview and hair care products; o.b.Tampons; Penaten and Natsuan The company is engaged in the manufacture and sale of a baby care products; PIZ Buin and Sundown sun care prod- broad range of products in the healthcare field. With over ucts; Reach toothbrushes; RoC skin care products; Shower 190 operating companies it conducts business in virtually to Shower personal care products; Splenda, a non-caloric all countries of the world. Johnson & Johnson's primary sugar substitute; Stayfree sanitary protection products; the interest, both historically and currently, has been in prod- broad family of Tylenol acetaminophen products; and Viactiv ucts related to human health and well-being. The company calcium supplements. These products are marketed princi- was organised in 1887. Its common stock is listed on the pally to the general public and distributed both to wholesal- New York Stock Exchange under the symbol JNJ and it is ers and directly to independent and chain retail outlets. headquartered in New Brunswick, New Jersey. The Pharmaceutical segment's principal worldwide fran- JNJ’s metrics are as follows: chises are in the antifungal, anti-infective, cardiovascular, dermatology, gastrointestinal, haematology, immunology, neurology, oncology, pain management, psychotropic, urol- Spot ($) 73.23 ogy and women's health fields. These products are distribut- Mkt Cap ($mn) 202,940 ed both directly and through wholesalers for use by health 12M trailing P/E 14.5 care professionals and the general public. In 2001, sales to 12M fwd P/E 13.3 three distributors, McKesson HBOC, Cardinal Distribution 10-year average P/E 16.7 and AmerisourceBergen Corp.
    [Show full text]
  • Title of Each Class Name of Each Exchange on Which Registered
    1 -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000 COMMISSION FILE NUMBER 1-3215 JOHNSON & JOHNSON (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) NEW JERSEY 22-1024240 (State of (I.R.S. Employer Incorporation) Identification No.) ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NEW JERSEY 08933 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED ------------------- ----------------------------------------- Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [X] The aggregate market value of the voting stock held by non-affiliates of the registrant on February 27, 2001 was approximately $133.8 billion.
    [Show full text]
  • [Propuesta De Mejora Del Proceso En Un Centro De Producción De Hilo
    [Propuesta de Mejora del Proceso en un Centro de Producción de Hilo Dental] MEMORIA PRESENTADA POR: [Johanny C. Ovalles Acosta] [Máster Universitario en Ingeniería de Organización y Logística] Convocatoria de defensa: [septiembre 2018] . Resumen Este reporte de investigación a desarrollar tiene como objetivo, analizar las principales razones por las que se generan eventos de No Calidad o No Conformes (NC) en un centro de producción de la planta de manufactura Johnson & Johnson Dental Care, R.D., dicho centro se encarga de producir subensambles que forman parte del hilo dental, siendo este el producto terminado o final que se manufactura en dicha planta. A fin de poder implementar acciones correctivas y preventivas para la eliminación o disminución de los eventos de No Calidad o No Conformes, se identificaron las principales herramientas de análisis de Causa Raíz, seleccionando el Diagrama de Ishikawa o también llamado Espina de Pescado para analizar profundamente la/s causa/s potenciales que generan la situación que se presenta en dicho centro. Del mismo modo la identificación de los mayores detractores que afectan el centro de producción, luego la verificación de los procedimientos e instrucciones de trabajo vigentes de dicho centro, a fin de retarlos contra la ejecución actual del proceso, igualmente identificar los cambios necesarios a implementar con el propósito de lograr una mejor manufactura y manejo de los subensambles y por consiguiente determinar los controles de calidad y las acciones recomendables a implementar para poder optimizar el proceso de manufactura de los subensambles. Summary: The objective of this investigation report to be developed is to analyze the main reasons of the generation of Non Quality or Non Conformances (NC) in a production center of Johnson & Johnson Dental Care, R.D.
    [Show full text]
  • Creative Leadership Tim O'toole
    TIM O’TOOLE CREATIVE LEADERSHIP timotoolecreative.com • [email protected] • 212•243•0148 OBJECTIVE: Identify new leadership role leveraging agency and in-house brand expertise in design, integrated marketing, and strategy management, to create inspired, motivated, and cohesive multi-disciplinary teams, and consistently deliver strategic content and upstream innovation in a clearly defined operational framework. Portfolio available upon request. 2016 - 2019 CREATIVE DIRECTOR: CONSULTING Ongoing relationships developing Branding, Visual Identity Systems, Package Design and Graphics, Interiors, and Design Strategy for multi-industry client base. 2014 - 2016 CREATIVE DIRECTOR: JOHNSON & JOHNSON, DESIGN CAPABILITIES Management of all Consumer, Healthcare, Pharmaceutical and Corporate design activities to generate consistent people-centered design brand experiences via insight and data synthesis, category knowledge, and cultural trend scouting. Activated new organization structure, defined and implemented Integrated Marketing Communication design programs, talent acquisition and development, upstream innovation, brand identity, graphics, industrial design, package design, retail merchandising, workplace design, agency oversight, external brand partnerships, corporate sponsorship programs, and process innovation. Team Size: 35 Recognition: US patents, J&J Standard of Leadership Awards, Industry / J&J Design Awards Brands: Neutrogena (Skincare and Cosmetics), Aveeno, Clean & Clear, RoC, Korres, Le Petit Marseillais, Dabao, Piz Buin,
    [Show full text]
  • Moats : the Competitive Advantages of Buffett and Munger Businesses
    Moats The Competitive Advantages Of Buffett & Munger Businesses By Bud Labitan First Edition Copyright © 2012 All rights reserved. Printed in the United States of America. No part of this book may be used or reproduced in any manner without permission. ISBN 978-1-105-41808-2 1 2 A truly great business must have an enduring “moat” that protects excellent returns on invested capital. ~ Warren Buffett How do you compete against a true fanatic? You can only try to build the best possible moat and continuously attempt to widen it. ~ Charlie Munger 3 4 TABLE OF CONTENTS INTRODUCTION CHAPTER 1: ACME BRICK COMPANY CHAPTER 2: AMERICAN EXPRESS CO. (AXP) CHAPTER 3: APPLIED UNDERWRITERS CHAPTER 4: BEN BRIDGE JEWELER CHAPTER 5: BENJAMIN MOORE & CO. CHAPTER 6: BERKSHIRE HATHAWAY GROUP CHAPTER 7: BERKSHIRE HATHAWAY HOMESTATE COMPANIES CHAPTER 8: BOATU.S. CHAPTER 9: BORSHEIMS FINE JEWELRY CHAPTER 10: BUFFALO NEWS CHAPTER 11: BURLINGTON NORTHERN SANTA FE CORP. CHAPTER 12: BUSINESS WIRE CHAPTER 13: BYD CHAPTER 14: CENTRAL STATES INDEMNITY COMPANY CHAPTER 15: CLAYTON HOMES CHAPTER 16: COCA COLA (KO) CHAPTER 17: CONOCOPHILLIPS (COP) CHAPTER 18: CORT BUSINESS SERVICES 5 CHAPTER 19: COSTCO WHOLESALE (COST) CHAPTER 20: CTB INC. CHAPTER 21: FECHHEIMER BROTHERS COMPANY CHAPTER 22: FLIGHTSAFETY CHAPTER 23: FOREST RIVER CHAPTER 24: FRUIT OF THE LOOM® CHAPTER 25: GARAN INCORPORATED CHAPTER 26: GATEWAY UNDERWRITERS AGENCY CHAPTER 27: GEICO AUTO INSURANCE CHAPTER 28: GENERAL RE CHAPTER 29: H.H. BROWN SHOE GROUP CHAPTER 30: HELZBERG DIAMONDS CHAPTER 31: HOMESERVICES OF AMERICA CHAPTER 32: IBM CHAPTER 33: INTERNATIONAL DAIRY QUEEN, INC. CHAPTER 34: ISCAR METALWORKING COMPANIES CHAPTER 35: JOHNS MANVILLE CHAPTER 36: JOHNSON & JOHNSON (JNJ) CHAPTER 37: JORDAN'S FURNITURE CHAPTER 38: JUSTIN BRANDS CHAPTER 39: KRAFT FOODS (KFT) 6 CHAPTER 40: LARSON-JUHL CHAPTER 41: LUBRIZOL CHAPTER 42: M&T BANK CORP (M&T BANK) CHAPTER 43: MARMON HOLDINGS, INC.
    [Show full text]